• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

头孢他洛滨-他唑巴坦对不同β-内酰胺类耐药表型阴沟肠杆菌复合体临床分离株的活性。

Activity of Ceftolozane-Tazobactam against Enterobacter cloacae Complex Clinical Isolates with Different β-Lactam Resistance Phenotypes.

机构信息

CHU Clermont-Ferrand, Laboratoire de Bactériologie et CNR de la Résistance aux Antibiotiques, Clermont-Ferrand, France.

UMR INSERM 1071 USC INRA2018, Université Clermont Auvergne, Clermont-Ferrand, France.

出版信息

Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00675-18. Print 2018 Sep.

DOI:10.1128/AAC.00675-18
PMID:29914962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6125531/
Abstract

The study evaluated the activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of complex (ECC). No difference was observed according to the ECC cluster. The activity greatly varied depending on the β-lactamase-producing profile: 100%, 67%, and 19% of wild-type, extended-spectrum β-lactamase (ESBL)-producing, and AmpC-overproducing strains, respectively, were susceptible to C/T. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-nonoverexpressing ECC isolates.

摘要

本研究评估了头孢洛扎他唑巴坦（C/T）对 94 株独特的复杂性（ECC）临床分离株的活性。根据 ECC 聚类，未观察到差异。根据产β-内酰胺酶的表型，其活性有很大差异：野生型、产超广谱β-内酰胺酶（ESBL）和产 AmpC 酶的菌株，对 C/T 的敏感性分别为 100%、67%和 19%。C/T 的使用可能对治疗某些由产 ESBL 但不表达 AmpC 的 ECC 分离株引起的感染有意义。

相似文献

1
Activity of Ceftolozane-Tazobactam against Enterobacter cloacae Complex Clinical Isolates with Different β-Lactam Resistance Phenotypes.头孢他洛滨-他唑巴坦对不同β-内酰胺类耐药表型阴沟肠杆菌复合体临床分离株的活性。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00675-18. Print 2018 Sep.
2
High minimum inhibitory concentrations among derepressed AmpC-beta-lactamase-producing complex isolates for ceftolozane with tazobactam.
Infect Control Hosp Epidemiol. 2020 May;41(5):631-633. doi: 10.1017/ice.2020.31. Epub 2020 Feb 28.
3
Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.解析铜绿假单胞菌头孢他啶-他唑巴坦耐药性的演变。
mBio. 2018 Dec 11;9(6):e02085-18. doi: 10.1128/mBio.02085-18.
4
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.头孢洛扎单药及与他唑巴坦联合对产超广谱β-内酰胺酶肠杆菌科细菌的体外活性
Antimicrob Agents Chemother. 2015 Aug;59(8):4521-5. doi: 10.1128/AAC.04498-14. Epub 2015 May 18.
5
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.2013 年至 2015 年期间，美国住院患者呼吸道标本中分离的铜绿假单胞菌和肠杆菌科细菌对头孢他洛滨-他唑巴坦的活性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02125-17. Print 2018 Mar.
6
[The expression of AmpC and extended-spectrum beta-lactamases among clinical isolates of enterobacter cloacae and its impact on antibiotics susceptibility].阴沟肠杆菌临床分离株中AmpC和超广谱β-内酰胺酶的表达及其对抗生素敏感性的影响
Zhonghua Yi Xue Za Zhi. 2002 Oct 10;82(19):1355-8.
7
Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.西班牙重症监护病房患者分离的铜绿假单胞菌和肠杆菌科细菌对头孢他洛滨/他唑巴坦的活性：SUPERIOR 多中心研究。
Int J Antimicrob Agents. 2019 May;53(5):682-688. doi: 10.1016/j.ijantimicag.2019.02.004. Epub 2019 Feb 12.
8
SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.产超广谱β-内酰胺酶的SHV型与阴沟肠杆菌对头孢吡肟敏感性降低有关。
J Clin Microbiol. 2005 Oct;43(10):5058-64. doi: 10.1128/JCM.43.10.5058-5064.2005.
9
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).头孢洛扎/他唑巴坦对亚太地区（不包括中国、澳大利亚和新西兰）引起的医疗保健相关感染的耐药肠杆菌科和铜绿假单胞菌的活性：来自抗菌监测计划（2013-2015 年）的报告。
Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.
10
Screening extended-spectrum beta-lactamase production in Enterobacter cloacae and Serratia marcescens using antibiogram-based methods.采用药敏试验基于方法检测阴沟肠杆菌和黏质沙雷菌产超广谱β-内酰胺酶。
J Microbiol Immunol Infect. 2010 Feb;43(1):26-34. doi: 10.1016/S1684-1182(10)60004-7. Epub 2010 Mar 29.

引用本文的文献

1
Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales.产AmpC肠杆菌科细菌所致感染的抗生素治疗
Pharmacy (Basel). 2024 Sep 21;12(5):142. doi: 10.3390/pharmacy12050142.
2
Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.用于革兰氏阴性医院获得性肺炎的新型抗生素
Antibiotics (Basel). 2024 Jul 5;13(7):629. doi: 10.3390/antibiotics13070629.
3
Activity of cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations on complex and in Spain (SMART 2016-2022).头孢吡肟、碳青霉烯类及新型β-内酰胺/β-内酰胺酶抑制剂组合在西班牙复杂感染中的活性（2016 - 2022年SMART研究）
JAC Antimicrob Resist. 2024 Jun 6;6(3):dlae087. doi: 10.1093/jacamr/dlae087. eCollection 2024 Jun.
4
Filling knowledge gaps related to AmpC-dependent β-lactam resistance in Enterobacter cloacae.填补阴沟肠杆菌 AmpC 依赖性β-内酰胺耐药相关的知识空白。
Sci Rep. 2024 Jan 2;14(1):189. doi: 10.1038/s41598-023-50685-1.
5
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.抗菌药物新视角：头孢他洛巴坦-他唑巴坦。
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0231820. doi: 10.1128/AAC.02318-20.
6
Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".对新型β-内酰胺-β-内酰胺酶抑制剂组合的耐药性：“进步的代价”。
Infect Dis Clin North Am. 2020 Dec;34(4):773-819. doi: 10.1016/j.idc.2020.05.001. Epub 2020 Sep 30.
7
Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance.耐多药革兰阴性菌所致血流感染的治疗
Antibiotics (Basel). 2020 Sep 22;9(9):632. doi: 10.3390/antibiotics9090632.
8
Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).头孢洛扎他唑巴坦与其他比较药物对革兰氏阴性杆菌的活性：来自监测抗菌药物耐药性趋势研究（SMART-巴西；2016-2017 年）的结果。
Braz J Infect Dis. 2020 Jul-Aug;24(4):310-321. doi: 10.1016/j.bjid.2020.05.010. Epub 2020 Jul 12.
9
AmpC β-lactamase-producing Enterobacterales: what a clinician should know.产 AmpCβ-内酰胺酶肠杆菌科细菌：临床医生须知。
Infection. 2019 Jun;47(3):363-375. doi: 10.1007/s15010-019-01291-9. Epub 2019 Mar 6.

本文引用的文献

1
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.作为监测项目“头孢洛扎-他唑巴坦敏感性评估项目”的一部分，对2013年至2016年在美国医院分离出的具有各种耐药模式的肠杆菌科细菌和铜绿假单胞菌进行头孢洛扎-他唑巴坦抗菌活性测试
Microb Drug Resist. 2018 Jun;24(5):563-577. doi: 10.1089/mdr.2017.0266. Epub 2017 Oct 17.
2
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.头孢洛扎/他唑巴坦对来自不列颠群岛的监测菌及“问题”肠杆菌科细菌、铜绿假单胞菌和非发酵菌的活性。
J Antimicrob Chemother. 2017 Aug 1;72(8):2278-2289. doi: 10.1093/jac/dkx136.
3
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).头孢洛扎/他唑巴坦对引起欧洲尿路感染和腹腔内感染的耐药肠杆菌科细菌及铜绿假单胞菌的活性：一项抗菌药物监测计划（2012 - 2015年）的报告
J Antimicrob Chemother. 2017 May 1;72(5):1386-1395. doi: 10.1093/jac/dkx009.
4
Inventory of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in France as Assessed by a Multicenter Study.一项多中心研究评估的法国产超广谱β-内酰胺酶肠杆菌科细菌清单
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01911-16. Print 2017 Mar.
5
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦：第二代β-内酰胺/β-内酰胺酶抑制剂组合
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
6
Complex Regulation Pathways of AmpC-Mediated β-Lactam Resistance in Enterobacter cloacae Complex.阴沟肠杆菌复合体中AmpC介导的β-内酰胺耐药的复杂调控途径
Antimicrob Agents Chemother. 2015 Dec;59(12):7753-61. doi: 10.1128/AAC.01729-15. Epub 2015 Oct 5.
7
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.在体外研究头孢洛扎/他唑巴坦对西班牙医疗机构分离的铜绿假单胞菌和肠杆菌科临床分离株的活性：CENIT 研究结果。
Int J Antimicrob Agents. 2015 Nov;46(5):502-10. doi: 10.1016/j.ijantimicag.2015.07.004. Epub 2015 Aug 10.
8
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.头孢洛扎单药及与他唑巴坦联合对产超广谱β-内酰胺酶肠杆菌科细菌的体外活性
Antimicrob Agents Chemother. 2015 Aug;59(8):4521-5. doi: 10.1128/AAC.04498-14. Epub 2015 May 18.
9
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).针对2011 - 12年在欧洲医院分离出的具有不同耐药模式的铜绿假单胞菌和肠杆菌科细菌测试头孢洛扎/他唑巴坦的抗菌活性。
J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10.
10
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.头孢洛扎他唑巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂组合，对多种耐药性革兰氏阴性杆菌具有活性。
Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.